A new report from FirstWord Pharma shifts the spotlight to the Institute for Clinical and Economic Review (ICER), and takes a deep dive into the drug pricing watchdog’s influence on prices, payers and health policy.
The report includes insights from a number of experts in market access and health technology assessment on how ICER could impact the pharmaceutical industry.
“ICER can share their data round cost-effectiveness with payers and then it is easier for payers to take decisions to put expensive drugs down the formulary tiers,” one expert, Shruti Desai, said. “Basically tiering decisions are going to be driven by ICER’s analysis.”
Learn more about this FirstWord report here.